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Abstract
Introduction
Danish women exit cervical cancer screening at age 65 years, but 23% of cervical cancer
cases occur beyond this age. In addition, due to gradual implementation of cervical cancer
screening, older women are underscreened by today´s standards. A one-time screening
with HPV test was therefore offered to Danish women born before 1948.
Methods
Register based study reporting histology diagnoses and conizations in women found HPV
positive in the one-time screening. Number and proportion of women with severe or non-
severe histology results were calculated for screened and HPV-positive women by age
group or region of residence. Number of women with biopsy and/or conization per case of
cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) or CIN3+ were also calcu-
lated by age groups and region.
Results
4,479 (4.1% of screened women) had positive HPV test. 94% of these had one or more
additional tests. 2,785 (62%) of HPV-positive women had histology results, and conization
was performed in 1,076 (24% of HPV-positive and 1% of all screened women). HPV positiv-
ity and CIN3+ detection varied little between regions, but the proportions of HPV positive
women undergoing histology varied between regions from 40% to 86% and the proportion
with conization from 13% to 36%. Correspondingly, the number of histologies and coniza-
tions per CIN3+ detected varied from 5.9 to 11.2 and 1.8 to 4.7, respectively. In total, 514
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CIN2+ (0.47% of screened women, 11% of HPV-positive) and 337 CIN3+ (0.31% of
screened women, 7.5% of HPV-positive) were diagnosed, including 37 cervical cancer
cases.
Discussion
HPV screening of insufficiently screened birth cohorts can potentially prevent morbidity and
mortality from cervical cancer but longer follow-up is needed to see if cancer incidence
declines in the screened women in the coming years. Management strategies differed
among regions which influenced the proportions undergoing biopsy/conization.
Introduction
Cervical cancer screening has substantially reduced the incidence of cervical cancer [1]. Most
countries in Europe recommend cervical screening of women up until the age of 60–65 years
[2]. In many high-income countries, however, the cervical cancer incidence in women aged
above 65 years is relatively high. This has led to considerations regarding optimal age to stop
screening [3,4].
Denmark is no exception: women exit the screening program at age 60–64 years, but 23%
of cervical cancer cases in 2011–16 were diagnosed in women aged 65 years or older [5]. This
attracted attention and gave rise to debate among clinicians, politicians, and non-governmen-
tal organizations on a possible extension of the upper age limit for screening. The Danish cer-
vical screening program was implemented gradually, until all women aged 23 to 59 years were
covered in 2006. In 2007, the upper age limit was extended to 64 years, and since 2012, the
national screening guidelines have recommended testing for high risk (hr) human papilloma-
virus (HPV) as an exit-test between age 60 and 64. Women aged below 60 are screened with
cytology [6,7].
Realizing that the history of the Danish cervical cancer screening program had left women
born before 1948 incompletely screened or unscreened [8], the government decided to offer a
one-time HPV screening test to women born before 1948 [9,10]. This initiative was imple-
mented in 2017–18, and 30% of invited women participated of whom 4.1% tested positive for
hr-HPV [9]. In this article, we report on histological findings among these HPV-positive
women with the aim of contributing to the evidence regarding cervical cancer screening
beyond the currently recommended upper age limit.
Material and methods
The one-time screening initiative for women born before 1948 has been described in detail
previously [9]. Briefly, the initiative was part of a wider, national plan for cancer developed by
the Ministry of Health, which provided for a single contact to women in the targeted birth
cohorts. No ongoing screening or reminders were included in the cancer plan for these
cohorts. The initiative was implemented by the five administrative regions of Denmark, fol-
lowing joint planning by the national health authorities and the regions. All women in the
targeted birth cohorts received a letter during 2017 from their region of residence with infor-
mation about the initiative and an invitation to contact their general practitioner (GP) for an
HPV screening test or, if needed, for individualized advice about participation. Denmark has a
tax-financed, public healthcare system and participation in the screening was voluntary and
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free of charge to the women. The GP collected a cervical sample which was analyzed for hr-
HPV at the public hospital pathology departments. Of 359,763 invited women, 108,585 (30%)
were screened, of whom 4,479 (4.1%) were positive for hr-HPV, in the following abbreviated
to HPV-positive [9].
Results of the initial HPV tests as well as triage and follow-up tests were recorded in the
Danish Pathology Register (DPR), which holds complete cytology and histology results from
all pathology departments in Denmark [11]. Test results for the 4,479 women who initially
tested HPV-positive were retrieved from 2017 to October 2019 using the civil registration
number, which provides a unique identifier for each woman. Data for this study was provided
from the Quality Assurance Program of the Danish Regions (RKKP) and the Danish Quality
Database for Cervical Cancer Screening (DKLS) aggregated by region or by 5-year groups of
birth-year.
Although the initiative was centrally planned, the five regions had some autonomy in
designing their screening algorithms, further testing, and management. The Capital region
recommended referral of all HPV-positive women for colposcopy. In the four other regions,
HPV type 16 and 18 were always recommended referral for colposcopy, and for other hr-
HPV-types, cytology was performed on the screening sample and colposcopy recommended if
atypical squamous cell of undetermined significance or worse (ASCUS+) was present. Other-
wise, repeated HPV testing after 12 months was recommended.
Histology diagnoses in the DPR are coded according to the cervical intraepithelial neoplasia
(CIN) classification. Histology was divided into severe diagnoses (CIN2, CIN3, cancer, and
unclassifiable CIN) and non-severe diagnosis without indication of treatment (CIN1 and nor-
mal histology). Histology diagnoses may stem from biopsies, conizations, or hysterectomies. If
more than one histology diagnosis was registered, the most severe was used for the analyses.
The following outcomes are reported by birth-year groups and by region:
• Proportion testing HPV-positive
• Proportion returning for further testing, i.e. followed up
• Proportion having histological examination performed
• Proportion with conization
• Proportion with severe histology (CIN2+ and CIN3+)
• Number of histologies and conizations per detected severe diagnosis (CIN2+ or CIN3+)
95% confidence intervals (CI) for proportions were calculated as Clopper-Pearson exact
method. Differences between proportions was tested with two-sample test. Analyses were per-
formed with STATA IC 15.1. This study was approved by the Danish Data Protection Agency
via the Central Denmark Region which serves as ethical clearance according to Danish
legislation.
Results
Of 108,585 screened women, 4,479 (4.1%) were HPV-positive, ranging from 4.3% in the youn-
gest screened cohorts to 3.2% in the oldest. Of the 4,479 HPV-positive women, 4,222 (94%)
had one or more additional tests performed during the period covered by this study; 2,785
(62% of HPV-positive, 2.5% of all screened women) had one or more histology result regis-
tered, 514 (11% of HPV positive, 0.47% of screened) had CIN2+, and 1,076 women (24% of
HPV-positive, 1% of all screened women) had conization performed, Table 1.
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Across all cohorts, about two-thirds of women for whom follow-up tests were registered
had a cervical histology diagnosis. Due to the lower proportion of HPV-positive women and
less follow-up in the older cohorts, the proportion with histology diagnosis varied from 2.7%
in the youngest to 1.5% in the oldest cohorts of screened women, and from 63% to 48% of
HPV-positive women. A similar pattern was seen for conization. In total, 1.0% of screened
women underwent conization varying from 1.0% in the youngest to 0.6% in the oldest cohort,
but in each cohort constituting about one-fourth of women with follow-up, Table 1.
Overall, CIN3 was diagnosed in 300 women and cervical cancer in 37. These cases consti-
tuted 0.31% of screened women and 7.5% of HPV-positive women. All cancer cases occurred
in women born after 1937, Table 2. For CIN2+, the proportions were 0.47% of screened
women and 11% of HPV-positive women. In total, 3.2 women underwent conization per
detected CIN3+ case, and these numbers varied little across cohorts, apart from the oldest
group where the numbers were small. For all histology results, including from biopsies, 8.3
women had histology performed for each CIN3+ case diagnosed, Table 2. Fig 1 shows the vari-
ation in follow-up screening outcomes by birth year group. Older birth year groups had less
follow-up examinations but less variation in CIN3+ detection.
The proportion of HPV-positive women varied from 3.4% of screened women in Southern
Denmark to 4.8% in Central Denmark (p< 0.0001), with the other regions in between,
Table 3. The follow-up proportions were high in all regions, but type of follow-up varied con-
siderably. Follow-up with histology varied from 1.8% of screened women in Southern Den-
mark to 3.5% in the Capital Region (p< 0.0001). In the Capital Region, 90% of women with
follow-up had histology performed, 42% in Central Denmark Region, with the other regions
in between. Conizations varied from 0.5% of screened women in Southern Denmark to 1.9%
Table 1. Danish women born before 1948 and HPV-screened in 2017–2018.
Screening outcome Birth year Total
1943–1947 1938–1942 1933–1937 1932 or earlier
Screened women 60,921 31,990 12,057 3,617 108,585
HPV-positive 2,621 1,322 420 116 4,479
% of screened (95% CI) 4.3% (4.1–4.5) 4.1% (3.9–4.4) 3.5% (3.2–3.8) 3.2% (2.7–3.8) 4.1% (4.0–4.2)
# with follow-up registered 2,513 1,246 376 87 4,222
% of HPV-positive (95% CI) 96% (95–97) 94% (93–95) 90% (86–92) 75% (66–83) 94% (94–95)
Histology performed1 1,661 817 251 56 2,785
% of screened (95% CI) 2.7% (2.6–2.9) 2.6% (2.4–2.7) 2.1% (1.8–2.4) 1.5% (1.2–2.0) 2.6% (2.5–2.7)
% of HPV-positive (95% CI) 63% (61–65) 62% (59–64) 60% (55–64) 48% (39–58) 62% (61–64)
% of women w/follow-up (95% CI) 66% (64–68) 66% (63–68) 67% (62–72) 64% (53–74) 66% (65–67)
Follow-up but no histology2 852 429 125 31 1,437
% of screened (95% CI) 1.4% (1.3–1.5) 1.3% (1.2–1.5) 1.0% (0.86–1.2) 0.85% (0.58–1.2) 1.3% (1.3–1.4)
% of HPV-positive (95% CI) 33% (31–34) 32% (30–35) 30% (25–34) 27% (19–36) 32% (31–33)
% of women w/follow-up (95% CI) 34% (32–36) 34% (32–37) 33% (28–38) 36% (26–47) 34% (33–35)
Conization performed 627 344 85 20 1,076
% of screened (95% CI) 1.0% (0.9–1.1) 1.1% (0.9–1.2) 0.7% (0.6–0.9) 0.6% (0.3–0.9) 1.0% (0.9–1.1)
% of HPV-positive (95% CI) 24% (22–26) 26% (24–28) 20% (16–24) 17% (11–25) 24% (23–25)
% of women w/follow-up (95% CI) 25% (23–27) 28% (25–30) 23% (18–27) 23% (15–33) 25% (24–27)
% of women w/histology (95% CI) 38% (35–40) 42% (39–46) 34% (28–40) 36 (23–50) 39% (37–40)
Numbers and proportions of women screened, HPV-positive, with follow-up, with histology, and with conization by birth-year group.
1: From biopsy or conization.
2: Follow-up with cytology and/or HPV-test.
https://doi.org/10.1371/journal.pone.0246902.t001
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Table 2. Histological outcome and proportions with<CIN2, CIN2+ and CIN3+ of screened women, of HPV-positive and of women with follow-up.
Histology outcome Birth year Total2
1943–1947 1938–1942 1933–1937 1932 or earlier
Women with histology1 1661 817 251 53 2782
No malignancy or dysplasia 1181 552 174 37 1944
CIN 1 163 84 29 5 281
CIN2 60 40 5 # 105
CIN 3/AIS 173 87 29 11 300
CIN unclassified 42 23 5 # 70
Cancer 21 16 0 0 37
Inconclusive or unknown 21 15 9 # 45
<CIN2 1344 636 203 42 2225
% of screened (95% CI) 2.2% (2.1–2.3) 2.0% (1.8–2.1) 1.7% (1.5–1.9) 1.2% (0.8–1.6) 2.0% (2.0–2.1)
% of HPV-pos. (95% CI) 51% (49–53) 48% (45–51) 48% (43–53) 36% (27–45) 50% (48–51)
% of women w/histology 81% (79–83) 78% (75–81) 81% (75–86) 75% (62–86) 80% (78–81)
CIN2+ 296 166 39 13 514
% of screened (95% CI) 0.49% (0.43–0.54) 0.52% (0.44–0.6) 0.32% (0.23–0.44) 0.36% (0.19–0.61) 0.47% (0.43–0.51)
% of HPV-pos. (95% CI) 11% (10–13) 13% (11–14) 9.3% (6.7–12) 11% (6.1–18) 11% (11–12)
% of women w/histology 18% (16–20) 20% (18–23) 16% (11–21) 23% (13–36) 18% (17–20)
CIN3+ 194 103 29 11 337
% of screened (95% CI) 0.32% (0.28–0.37) 0.32% (0.26–0.39) 0.24% (0.16–0.35) 0.30% (0.15–0.54) 0.31% (0.28–0.35)
% of HPV-pos.(95% CI) 7.4% (6.4–8.5) 7.8% (6.4–9.4) 6.9% (4.7–9.8) 9.5% (4.8–16) 7.5% (6.8–8.3)
% of women w/histology 12% (10–13) 13% (10–15) 12% (7.9–16) 20% (10–32) 12% (11–13)
Numbers of procedures per diagnosis
Conizations per CIN2+ case (95% CI) 2.1 (1.8–2.4) 2.1 (1.8–2.5) 2.2 (1.5–3.2) 1.5 (0.8–3.1) 2.1 (1.9–2.3)
Conizations per CIN3+ case (95% CI) 3.2 (2.8–3.8) 3.3 (2.7–4.2) 2.9 (1.9–4.5) 1.8 (0.9–3.8) 3.2 (2.8–3.6)
Histology performed per CIN2+ case 5.6 (5.0–6.3) 4.9 (4.2–5.8) 6.4 (4.6–9.0) 4.3 (2.4–7.9) 5.4 (4.9–6.0)
Histology performed per CIN3+ case 8.6 (7.4–9.9) 7.9 (6.5–9.7) 8.7 (5.9–12.7) 5.1 (2.7–9.7) 8.3 (7.4–9.3)
Conizations per CIN2+ or CIN3+ detected case by birth-year group. For women with more than one histology diagnosis, the most severe is used.
1: From biopsy or conization.
2: Cells with fewer than 3 women are excluded for reasons of privacy (marked #). Totals may thus differ between tables.
https://doi.org/10.1371/journal.pone.0246902.t002
Fig 1. Proportions of women who were HPV positive, had histology performed, had CIN3+, or underwent
conization, by birth year, compared to national average.
https://doi.org/10.1371/journal.pone.0246902.g001
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in Northern Denmark (p< 0.0001). In total, 0.31% of screened women had CIN3+ detected,
Table 4.
As shown in Fig 2 and Table 3, quite different proportions of screened women underwent
biopsy and/or conization in the five regions, in spite of smaller variations in HPV positivity
rate and CIN3+ detection. Accordingly, the number of conizations per CIN3+ differed sub-
stantially between regions from 1.8 in Southern Denmark to 4.7 in the Capital Region, Table 4.
The number of women with histology to CIN3+ cases diagnosed varied between regions, with
Capital and Zealand regions above the national average. Capital Region had the highest num-
bers of both histology and conizations per CIN3+ case, whereas North Denmark Region had a
high number of conization per CIN3+ case, while the number of histology per CIN3+ case was
below the national average.
Discussion
Main findings
In 2017, 108,585 Danish women aged 69 years or older had cervical samples tested for HPV,
and 4.1% were HPV-positive. By far the majority of the HPV-positive women had one or more
follow-up tests taken, and about two-thirds had at least one histology result. Conization was
performed in 1% of screened women, corresponding to 24% of HPV-positive women. Cervical
cancer was detected in 37 women, and CIN3 in 300 women, which was a CIN3+ detection rate
of 0.31% in screened women and of 7.5% in HPV-positive women. More than three women
underwent conization per detected CIN3+ case. Proportions of screened women testing
Table 3. Numbers and proportions of women screened, HPV positive, with follow-up, with histology, and with conization by region.
Screening outcome Region1 Total
Capital Zealand South Central North
Screened women 30,498 17,807 25,212 23,654 11,414 108,585
HPV-positive 1,246 736 855 1,130 512 4,479
% of screened (95% CI) 4.1% (3.9–4.3) 4.1% (3.8–4.4) 3.4% (3.2–3.6 4.8% (4.5–5.0) 4.5% (4.1–4.9) 4.1% (4.0–4.2)
# with follow-up test(s) 1,193 688 789 1,078 474 4,222
% of HPV positive (95% CI) 96% (94–97) 93% (91–95) 92% (90–94) 95% (94–97) 93% (90–95) 94% (94–95)
Histology performed2 1,073 488 451 453 320 2,785
% of screened (95% CI) 3.5% (3.3–3.7) 2.7% (2.5–3.0) 1.8% (1.6–2.0) 1.9% (1.7–2.1) 2.8% (2.5–3.1) 2.6% (2.5–2.7)
% of HPV positive (95% CI) 86% (84–88) 66% (63–70) 53% (49–56) 40% (37–43) 63% (58–67) 62% (61–64)
% of women w/follow-up (95% CI) 90% (88–92) 71% (67–74) 57% (54–61) 42% (39–45) 68% (63–72) 66% (65–67)
Follow-up but no histology3 120 200 338 625 154 1,437
% of screened (95% CI) 0.39% (0.33–0.47) 1.1% (0.97–1.3) 1.3% (1.2–1.5) 2.6% (2.4–2.9) 1.3% (1.1–1.6) 1.3% (1.3–1.4)
% of HPV-positive (95% CI) 9.6% (8.0–11) 27% (24–31) 40% (36–43) 55% (52–58) 30% (26–34) 32% (31–33)
% of women w/follow-up (95% CI) 10% (8.4–12) 29% (26–33) 43% (39–46) 58% (55–61) 32% (28–37) 34% (33–35)
Conization performed 449 130 136 144 217 1,076
% of screened (95% CI) 1.5% (13–16) 0.73% (0.61–0.87) 0.54% (0.45–0.64) 0.6% (0.51–0.71) 1.9% (1.7–2.2) 1.0% (0.9–1.1)
% of HPV-positive (95% CI) 36% (33–39) 18% (15–21) 16% (14–19) 13% (11–15) 42% (38–47) 24% (23–25)
% of women with follow-up (95% CI) 38% (35–40) 19% (16–22) 17% (15–20) 13% (11–16) 46% (41–50) 25% (24–27)
% of women with histology (95% CI) 42% (39–45) 27% (23–31) 30% (26–35) 32% (28–36) 68% (62–73) 39% (37–40)
1: The full names of the Danish regions are Capital Region, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region.
2: From biopsy or conization.
3: Follow-up with cytology and/or HPV-test.
https://doi.org/10.1371/journal.pone.0246902.t003
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HPV-positive, undergoing histology or conization varied little below age 79 but were lower in
women above this age. CIN3+ detection rates were similar across age.
While the CIN3+ detection rates varied little across the five Danish regions, there was a
considerable variation in proportions of women undergoing histology and/or conization. As a
consequence, there was approximately a two-fold variation in the numbers of biopsies/coniza-
tions per severe histology across regions.
Other studies
A Swedish study including 1,051 women aged 60–89 years found that 4.1% were HPV- positive
[12]. For HPV-positive women, testing was repeated after 3 months, and if negative again at 12
months. Overall, 30 (3%) women had two positive HPV-tests within one year, and 30% of
those positive on first test were negative on both repeat-tests. In another Swedish study, where
women initially HPV-negative were retested after a mean interval of 3.2 years, 2.6% were
HPV-positive, of whom 52% were positive again on repeat-test after an average of 2.5 months
[13]. In both studies, women with two positive HPV-tests had a high prevalence of CIN on his-
tology, although mainly CIN1, but few had detectable cytological changes. Comparable results
Table 4. Histological outcome and proportions with<CIN2, CIN2+ and CIN3+ of screened women, of HPV-positive and of women with follow-up. Conizations
per CIN2+ or CIN3+ detected case by region.
Histology outcome Region1 Total3
Capital Zealand South Central North
Women with histology2 1,073 488 451 453 319 2,784
Normal histology 789 376 318 273 188 1,944
CIN 1 90 26 32 77 56 281
CIN2 39 24 12 16 15 106
CIN 3/AIS 87 43 63 62 45 300
CIN unclassified 45 6 7 12 # 70
Cancer 9 6 13 6 3 37
Histology inconclusive or unknown 14 7 6 7 12 46
<CIN2 879 402 350 350 244 2225
% <CIN2 of screened women (95% CI) 2.9% (2.7–3.1) 2.3% (2.0–2.5) 1.4% (1.2–1.5) 1.5% (1.3–1.6) 2.1% (1.9–2.4) 2.0% (2.0–2.1)
% <CIN2 of HPV positive (95% CI) 71% (68–73) 55% (51–58) 41% (38–44) 31% (28–34) 48% (43–52) 50% (48–51)
% <CIN2 of women with histology (95% CI) 82% (79–84) 82% (79–86) 78% (73–81) 77% (73–81) 76% (71–81) 80% (78–81)
CIN2+ 180 79 95 96 64 514
% CIN2+ of screened women (95% CI) 0.59% (0.51–0.68) 0.44% (0.35–0.55) 0.38% (0.30–0.46) 0.41% (0.33–0.50) 0.56% (0.43–0.72) 0.47% (0.43–0.51)
% CIN2+ of HPV positive (95% CI) 14% (13–17) 11% (9–13) 11% (9–13) 8% (7–10) 13% (10–16) 11% (11–12)
% CIN2+ of women with histology (95% CI) 17% (15–19) 16% (13–20) 21% (17–25) 21% (17–25) 20% (16–25) 18% (17–20)
CIN3+ 96 49 76 68 48 337
% CIN3+ of screened women (95% CI) 0.31% (0.26–0.38) 0.28% (0.20–0.36) 0.30% (0.24–0.38) 0.29% (0.22–0.36) 0.42% (0.31–0.58) 0.31% (0.28–0.35)
% CIN3+ of HPV positive (95% CI) 7.7% (6.3–9.3) 6.7% (5.0–8.7) 8.9% (7.1–11) 6.0% (4.7–7.6) 9.4% (7.0–12) 7.5% (6.8–8.3)
% CIN3+ of women with histology (95% CI) 8.9% (7.3–11) 10% (7.5–13) 17% (14–21) 15% (12–19) 15% (11–19) 12% (11–13)
Numbers of procedures per diagnosis
Conizations per CIN2+ case (95% CI) 2.5 (2.1–3.0) 1.6 (1.2–2.2) 1.4 (1.1–1.9) 1.5 (1.2–1.9) 3.4 (2.6–4.5) 2.1 (1.9–2.3)
Conizations per CIN3+ case (95% CI) 4.7 (3.8–5.8) 2.7 (1.9–3.7) 1.8 (1.4–2.4) 2.1 (1.6–2.9) 4.5 (3.3–6.2) 3.2 (2.8–3.6)
Histology performed per CIN2+ case (95% CI) 6.0 (5.1–7.0) 6.2 (4.9–7.8) 4.7 (3.8–5.9) 4.7 (3.8–5.9) 5.0 (3.8–6.5) 5.4 (4.9–6.0)
Histology performed per CIN3+ case (95% CI) 11.2 (9.1–13.8) 10.0 (7.4–13.3) 5.9 (4.7–7.6) 6.7 (5.2–8.6) 6.7 (4.9–9.0) 8.3 (7.4–9.3)
1: The full names of the Danish regions are Capital Region, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region.
2: From biopsy or conization.
3: Cells with fewer than 3 women are excluded for reasons of privacy (marked #). Totals may thus differ between tables.
https://doi.org/10.1371/journal.pone.0246902.t004
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were obtained in another study where HPV-test was performed on self-collected samples [14].
When retesting HPV-positive or HPV-negative women, these studies thus demonstrated that
test results in elderly women vary over even short time spans, although it is unknown to which
extent this is due to cleared infections, reinfection, reactivation of latent HPV-infection or dif-
ficulty in obtaining representative samples from elderly women. In these Swedish studies,
fewer severe histology lesions were found than in ours. This may be related to sample size,
selection of studied women, to screening histories of studied women, or to the historically
lower cervical cancer incidence in Sweden than in Denmark [15].
A Danish GRADE-based evidence review on management of elderly, HPV-positive women
concluded that there is insufficient evidence on how to ensure reduction in cervical cancer risk
while minimizing overtreatment [16]. Surveillance over time is complicated by the difficulty in
obtaining representative samples from the cervix due to the age-related changes, and the Dan-
ish guidelines therefore recommend considering conization in women where the transforma-
tion zone cannot be visualized and/or biopsies have been unrepresentative.
The Horizon study compared screening by cytology to different HPV assays in Denmark
[17]. For women aged 30–65 years screened with Cobas HPV test (which was also used in
most regions for the one-time HPV screening of older women), the study found 129 biopsies
and 37 CIN3+ cases among 465 women positive on Cobas, i.e. 8% of HPV positive women had
CIN3+, and 3.5 biopsies were performed per CIN3+ case diagnosed.
A woman’s risk of cervical cancer in old age is related to her screening history [18,19], and
at the population level, the cervical cancer incidence in a specific age-group depends on the
screening history of the birth cohorts making up that age-group at that point in time [8]. The
Danish data showed a steady decrease in HPV-prevalence after the age of 35 years [9]. 82% of
cervical cancer cases diagnosed in women aged above 60 years occurred in never or insuffi-
ciently screened women, and the average age of non- or insufficiently screened cancer patients
was 76 years, the same age as cancer incidence peaks in old age [9,20]. However, the Danish
Pathology Register is only complete after 1998, and the screening history of older women is
therefore underreported in the register. Consequently, studies show an increase in proportion
screened over time, reflecting not only increased screening but also increased completeness of
the pathology register [21].
Fig 2. Regional proportions of women who were HPV positive, had histology performed, had CIN3+, or
underwent conization, compared to national average.
https://doi.org/10.1371/journal.pone.0246902.g002
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A cohort study of more than 500,000 Swedish women found that screening between age 61
and 65 years was beneficial for women with an insufficient screening history, while there was
no significant reduction in cervical cancer risk up to age 80 years in women adequately
screened with normal test results at age 51–60 [18].
Strengths and limitations
The availability of the national pathology register and unique identifiers ensured complete fol-
low-up. However, data on deaths and emigrations were not available, and we were therefore
unable to censor these women in the analysis. At the population level, we know that the birth
cohorts targeted by the one-time HPV-screening were insufficiently screened, but individual
data on the screening history, previous histology findings or therapeutic procedures were not
available, as the pathology register data are incomplete before 1998.
For some women, conization was performed after a biopsy had revealed a severe lesion, but
for other women the procedure was diagnostic, when a representative biopsy could not be
obtained. For some women, a conization may have been performed even in case of a non-
severe/no lesion to avoid lengthy follow-up with repeated cervical sampling. Some women
may still be in follow-up with HPV test and/or biopsy and may still be conizised after the
period covered in this study. Conization rates could thus be slightly higher than reported here,
as a decision on end of follow-up is not coded.
Women whose HPV screening test was negative were not retested, so intermittent HPV-
positivity, as in the Swedish studies referenced above, would not have been detected, and the
prevalence of histological lesions in women testing HPV negative was unknown. This limits
the ability of the study to fully estimate the cancer preventive effect of a single HPV test in
these age groups.
Part of the variation between regions could theoretically stem from differences in age distri-
bution. The aggregate RKKP data did not allow for age adjustment, but there is little difference
across regions in the age distribution of women in the studied age-range [22]. We consider it
unlikely that age specific participation in screening should vary across regions, and conse-
quently we consider it unlikely that the observed regional differences in histology and coniza-
tion rate derived from difference in age distributions.
Clinical implications
The European guidelines for cervical cancer screening recommend that women exit cervical
cancer screening at age 60–65 years provided they have had a recent negative test [23]. The US
preventive services task force recommends against screening of women older than 65 years if
they have had adequate prior screening and are not at high risk for cervical cancer [24].
A possible extension of existing screening programs beyond age 65 years has been subject
of both scientific and political considerations in many countries. In Denmark, the decision
was to target in incompletely screened birth cohorts with the one-time HPV screening
described here. Our results suggest that, for these cohorts, HPV screening can potentially pre-
vent some of the morbidity and mortality from cervical cancer, as severe lesions (CIN3+) were
detected in 7.5% of HPV-positive women, including 37 women with cervical cancer. However,
not all CIN3+ cases progress to cancer, and some of the 37 detected cervical cancer cases
might not have become symptomatic in the women’s remaining lifetime. Whether this screen-
ing intervention translates into fewer cervical cancer cases and deaths will be visible only after
a longer follow-up.
The results may not, however, be generalizable to birth cohorts after 1948 who have had a
systematic screening offer throughout their adult life. It is also important to note that, although
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women older than 65 years constitute an increasing proportion of cervical cancer cases, the
incidence in older women has declined over the past decades [15,25], reflecting the progres-
sively lower risk in each birth cohort [8]. The age-specific mortality has also declined over time
[15]. With primary HPV screening being implemented in many countries, the risk in elderly
women may be even lower in the future.
An alternative to a general extension of screening age might be to consider more personal-
ized approaches, factoring in each woman´s age, screening history, comorbidities, general
health and expected remaining lifespan [26] but more evidence is needed to estimate effects of
both general and personalized strategies. In Denmark, complete cervical cancer screening
results are available from the Danish Pathology Register for birth cohorts aging in the future,
thus enabling studies comparing cancer risk after screening age for women who did or did not
meet exit criteria, including women whose exit test was an HPV test.
In all screening initiatives, it is important to consider the potential harms in addition to the
benefits. Although conization is generally considered a minor procedure, the risk of bleeding
and complications like perforations may be elevated in older women, and age-related anatomi-
cal changes may render the procedure more difficult. In addition, the therapeutic effect of con-
ization is not well documented for women over 60 years [16]. On the other hand, obtaining
representative biopsies in older women is not always possible and therefore conization may be
necessary for providing a diagnosis and can be preferable to avoid lengthy follow-up with
repeated cervical sampling [16]. As shown in this study, the choice of management strategy
has an important impact on the number of biopsies/conizations per findings of CIN2+ or
CIN3+, and conceivably also on the number of women recalled for repeated tests in the
absence of conization. Although differences in study design do not allow for direct comparison
with the Horizon study, the results do suggest that the yield of CIN3+ compared to the number
having histology results is less favorable for older women, with 8.3 histologies per CIN3+ in
our study vs. 3.5 in Horizon.
Conclusion
To address the concern about the relatively high proportion of cervical cancer cases diagnosed
beyond screening age, in 2017, a one-time HPV-screening initiative was offered to Danish
women born before 1948. These birth cohorts had not been offered sufficient systematic
screening earlier in life. In total, 4.1% of participating women tested HPV-positive, and out of
those 7.5% had CIN3+ detected. While these proportions varied little across the five Danish
regions, there were considerable regional differences in proportions of women undergoing
biopsy and conization, reflecting differences in management strategies.
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